from the January 2014 issue

MediWound planning $100m Wall Street IPO

The chronic wounds and burns treatment company is planning to hold the offering at a company value of $450-500 million.

MediWound Ltd., which develops treatments for chronic wounds and burns is in talks with underwriters for a Wall Street IPO in the second quarter of 2014. The company plans to raise $100 million at a company value of $450-500 million.

Clal Biotechnology Industries Ltd. (TASE: CBI) owns 63% of MediWound. The company's NexoBrid gel for the removal of burn wound eschar has successfully completed clinical development and is approved and ready to launch in Europe.

Reprinted from the Israel High-Tech & Investment Report January 2014

Click HERE to request further information.
Click HERE to go BACK.